Allarity Therapeutics wins Japan patent for stenoparib DRP companion diagnostic

• Allarity Therapeutics won a Japanese patent covering its DRP companion diagnostic for stenoparib, extending protection in Japan to 2039.
• Patent covers gene-expression methods to predict clinical benefit from stenoparib, supporting patient selection in development programs.
• Company cited prior DRP patent protection in the US through April 2042, with additional coverage in parts of Europe and Australia.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Allarity Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-100350), on September 16, 2026, and is solely responsible for the information contained therein.